Casein kinase 2 subunit alpha mRNA (CK2α mRNA) (CK2α mRNA)

Casein kinase 2 subunit alpha (CK2α) mRNA is the messenger RNA transcript of the CSNK2A1 gene, which encodes the catalytic subunit of the protein kinase CK2. CK2 is a ubiquitous and constitutively active serine/threonine kinase that plays a critical role in regulating cell growth, proliferation, and survival by phosphorylating hundreds of substrates. In many human cancers, CK2α is overexpressed, contributing to the suppression of apoptosis and the promotion of oncogenic signaling pathways such as PI3K/Akt and NF-κB. Targeting the CK2α mRNA using RNA interference (RNAi) or antisense oligonucleotides (ASOs) provides a strategy to specifically downregulate the expression of the CK2α protein, thereby inhibiting its pathological activity. This approach aims to overcome the limitations of small-molecule inhibitors, such as potential off-target effects on other kinases and compensatory mechanisms involving the CK2α' isoform. Preclinical research has demonstrated that silencing CK2α mRNA can effectively induce cancer cell death and enhance the efficacy of conventional chemotherapeutic agents. Additionally, CK2 has been implicated in viral infections and neurodegenerative diseases, making its mRNA a potential target for broader therapeutic applications. Delivery of these RNA-based therapeutics often involves specialized nanocarriers to ensure stability and uptake by target cells.

Other names

CSNK2A1 mRNACasein kinase II alpha mRNACK2 alpha mRNACK2A1 mRNA

RNA interference and antisense inhibition leading to mRNA degradation and reduced protein translation